Skip to main content
Top
Published in: Clinical Rheumatology 12/2018

01-12-2018 | Brief Report

Clinical description of patients with cytoplasmic discrete dots pattern (lysosome) on indirect immunofluorescence on HEp-2 cells

Authors: Martin Brom, Carolina Eva Carrizo, Roberto Miguel Arana, Cecilia Nora Pisoni

Published in: Clinical Rheumatology | Issue 12/2018

Login to get access

Abstract

The cytoplasmic discrete dot (CDD) pattern is an unusual finding in indirect immunofluorescence, and its clinical value is unknown. To describe the clinical characteristics of patients with CDD pattern on indirect immunofluorescence (IIF) from our laboratory database and to evaluate possible associations with other autoantibodies and autoimmune diseases. This is a retrospective descriptive study. We included all patients with CDD pattern on IIF in HEp-2 cells with a titer equal or greater than 1/80, using a database of all IIF performed in a reference immunology and rheumatology laboratory between 2007 and 2015. Data on demographics, past medical history, and relevant laboratory findings were recorded and analyzed. We performed 13.056 IIF on HEp-2 cells tests between January 1, 2007 and December 31, 2015, with 6075 positive results. Among them, 5447 had nuclear pattern, 55 had both nuclear and cytoplasmic pattern, and 573 had cytoplasmic pattern. Only 21 showed a CDD pattern. Four patients were excluded since they did not have medical records at the institution. The prevalence of the CDD pattern in our laboratory was 0.35%. The median age was of 62.3 years (SD 9.16) and 100% were female. Fifty-three percent (9/17) had an autoimmune disease, Hashimoto’s thyroiditis (4/9) being the most frequent one. In conclusion, cytoplasmic discrete dot pattern is an uncommon finding and its clinical value is uncertain. However, in our study, 53% of the patients had an autoimmune disease.
Literature
3.
go back to reference Selak S, Chan EK, Schoenroth L, Senécal JL, Fritzler MJ (1999) Early endosome antigen. 1: an autoantigen associated with neurological diseases. J Investig Med 47:311–318PubMed Selak S, Chan EK, Schoenroth L, Senécal JL, Fritzler MJ (1999) Early endosome antigen. 1: an autoantigen associated with neurological diseases. J Investig Med 47:311–318PubMed
6.
go back to reference Kain R, Matsui K, Exner M, Binder S, Schaffner G, Sommer EM, Kerjaschki D (1995) A novel class of autoantigens of anti-neutrophil cytoplasmic antibodies in necrotizing and crescentic glomerulonephritis: the lysosomal membrane glycoprotein h-lamp-2 in neutrophil granulocytes and a related membrane protein in glomerular endothelial cell. J Exp Med 181:585–597CrossRef Kain R, Matsui K, Exner M, Binder S, Schaffner G, Sommer EM, Kerjaschki D (1995) A novel class of autoantigens of anti-neutrophil cytoplasmic antibodies in necrotizing and crescentic glomerulonephritis: the lysosomal membrane glycoprotein h-lamp-2 in neutrophil granulocytes and a related membrane protein in glomerular endothelial cell. J Exp Med 181:585–597CrossRef
Metadata
Title
Clinical description of patients with cytoplasmic discrete dots pattern (lysosome) on indirect immunofluorescence on HEp-2 cells
Authors
Martin Brom
Carolina Eva Carrizo
Roberto Miguel Arana
Cecilia Nora Pisoni
Publication date
01-12-2018
Publisher
Springer London
Published in
Clinical Rheumatology / Issue 12/2018
Print ISSN: 0770-3198
Electronic ISSN: 1434-9949
DOI
https://doi.org/10.1007/s10067-018-4305-x

Other articles of this Issue 12/2018

Clinical Rheumatology 12/2018 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine